Clinical Laserthermia Systems AB Class B (DE:LS60)
FRANKFURT:LS60
LS60 Stock Chart & Stats
€0.59
<€0.01(0.74%)
At close: 4:00 PM EST
€0.59
<€0.01(0.74%)
Day’s Range― - ―
52-Week Range€0.19 - €1.16
Previous CloseN/A
Volume0.00
Average Volume (3M)75.00
Market Cap
€14.25M
Enterprise Value€107.02M
Total Cash (Recent Filing)€21.55M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta3.49
Next Earnings
May 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding31,163,593
10 Day Avg. Volume175
30 Day Avg. Volume75
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.55
Price to Sales (P/S)10.18
P/FCF Ratio-4.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)€5.07M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet StrengthA near-zero debt position and meaningful equity capitalization reduce insolvency risk and preserve financial flexibility over months. This balance sheet strength supports continued clinical commercialization efforts, allows access to non-dilutive funding or bridge financing, and cushions operating volatility while the company scales.
Recurring Revenue Model PotentialA business model that pairs high-value installed systems with per-procedure consumables and services creates an annuity-like revenue stream as procedures scale. Durable consumable and service demand from installed sites can improve margin visibility and create long-term customer lock-in as adoption grows.
Improving Cash Burn And Operating LossesSequential improvement in operating losses and reduced cash burn suggests management is narrowing operational inefficiencies. If sustained, these trends lower near-term financing needs, extend runway for commercialization, and indicate progress toward a sustainable cost structure over the coming months.
Bears Say
Small, Volatile Revenue BaseA small and declining top line undermines scale economics and makes it harder to cover fixed costs from installed systems. Volatile revenue also complicates capacity planning, delays predictable consumable reorders, and increases execution risk for commercial rollouts over the next several months.
Persistent Negative Cash FlowConsistent, sizable negative operating and free cash flow forces reliance on external financing or cash reserves. This constrains the company's ability to invest in sales, clinical studies, and regulatory work, raises dilution or refinancing risk, and pressures strategic flexibility over the medium term.
Deep Negative Margins And Profitability GapExtremely negative gross and net margins indicate the core unit economics are currently loss-making. Without a clear and sustained path to positive gross margins, the company risks continued equity erosion and will struggle to demonstrate durable profitability to support long-term commercialization investments.
LS60 FAQ
What was Clinical Laserthermia Systems AB Class B’s price range in the past 12 months?
Clinical Laserthermia Systems AB Class B lowest stock price was €0.19 and its highest was €1.16 in the past 12 months.
What is Clinical Laserthermia Systems AB Class B’s market cap?
Clinical Laserthermia Systems AB Class B’s market cap is €14.25M.
When is Clinical Laserthermia Systems AB Class B’s upcoming earnings report date?
Clinical Laserthermia Systems AB Class B’s upcoming earnings report date is May 15, 2026 which is in 33 days.
How were Clinical Laserthermia Systems AB Class B’s earnings last quarter?
Clinical Laserthermia Systems AB Class B released its earnings results on Feb 20, 2026. The company reported -€0.035 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.035.
Is Clinical Laserthermia Systems AB Class B overvalued?
According to Wall Street analysts Clinical Laserthermia Systems AB Class B’s price is currently Overvalued.
Does Clinical Laserthermia Systems AB Class B pay dividends?
Clinical Laserthermia Systems AB Class B does not currently pay dividends.
What is Clinical Laserthermia Systems AB Class B’s EPS estimate?
Clinical Laserthermia Systems AB Class B’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Clinical Laserthermia Systems AB Class B have?
Clinical Laserthermia Systems AB Class B has 31,163,593 shares outstanding.
What happened to Clinical Laserthermia Systems AB Class B’s price movement after its last earnings report?
Clinical Laserthermia Systems AB Class B reported an EPS of -€0.035 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -23.125%.
Which hedge fund is a major shareholder of Clinical Laserthermia Systems AB Class B?
Currently, no hedge funds are holding shares in DE:LS60
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Clinical Laserthermia Systems AB Class B
Clinical Laserthermia Systems AB (publ) develops treatment tools for diseased tissue under the TRANBERG brand in Sweden. The company offers TRANBERG, a thermal therapy system designed to deliver laser energy to heat the target tissue. It also provides mobile laser unit, a controlling component with a wavelength of 1064 nanometers provides multiple options to control treatment. In addition, the company offers various gauge laser applicators, as well as provides temperature and treatment monitoring devices. Clinical Laserthermia Systems AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.
Technical Analysis
SpectraCure AB
―
Luxbright AB
―
Scandinavian Real Heart AB
―
Nosa Plugs AB
―
Arcoma AB
―